- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07681310
GreenArt: Nutrikinetics and Bioavailability Studies
26. juni 2026 opdateret af: Fytexia
Baccharis-type Propolis Extract, GreenArt: Nutrikinetics and Bioavailability Studies
The aim of this study is to investigate phenolic compounds from GreenArt, a baccharis-type propolis ingredient, bioavailability and nutrikinetics by measuring urinary excretion and metabolic profile over 48h by means of high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS).
The study follows a cross-over, double-blind, randomized and placebo control design on 10 healthy subjects.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
- Kosttilskud: GreenArt D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.
- Kosttilskud: GreenArt 4D is a baccharis-type propolis powder extract containing phenolic compounds such as prenylated phenylpropanoids derived from hydroxycinnamic acids and flavonoids.
- Kosttilskud: Placebo
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
10
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Julien Cases, PhD
- Telefonnummer: +33467219098
- E-mail: jcases@biotexia.com
Studiesteder
-
-
Murcia
-
Guadalupe, Murcia, Spanien, 30107
- UCAM Universidad Católica San Antonio de Murcia
-
Kontakt:
- Linda H. Chung, PhD
- Telefonnummer: + 34 968 278 611
- E-mail: lhchung@ucam.edu
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male and female with 40% min. and 60% max. of each sex.
- Aged 25 to 69 years old
- BMI range (18.5 - 29.99)
- In good general health as evidenced by medical history
- Ability to take oral supplementation and be willing to adhere to the regimen
- Agreement to adhere to Lifestyle Considerations (controlled diet) throughout study duration
Exclusion Criteria:
- Current use of any medication or food supplement
- Antibiotic use less than 12 weeks before the study
- Pregnancy or lactation
- Known allergic reactions to components of the supplement, i.e., bee products (specially propolis) and known allergy (general)
- Metabolic disorders or any kind of disease
- Current smoker
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: GreenArt D
This arm receives 150 mg of GreenArt, a baccharis-type propolis phenolic extract
|
GreenArt D contains 150 mg of GreenArt
|
|
Eksperimentel: GreenArt 4D
This arm receives 600 mg of GreenArt, a baccharis-type propolis phenolic extract
|
GreenArt 4D contains 600 mg of GreenArt
|
|
Placebo komparator: Placebo
This arm receives 150 mg of mix carriers of the GreenArt ingredient, a baccharis-type propolis phenolic extract
|
Placebo is composed of the carriers of GreenArt : gum arabic, sucrose and silicon dioxide mix.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in plasma area under the curve (AUC) of phenolic metabolites after acute ingestion of the supplement/placebo
Tidsramme: Baseline (pre-ingestion) to 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the area under the curve (0-24 hour) in nmol/L-h is measured.
|
Baseline (pre-ingestion) to 24 hour post-ingestion
|
|
Change in plasma maximal concentration (Cmax) of phenolic metabolites after acute ingestion of the supplement/placebo
Tidsramme: Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the maximal concentration in nmol/L is measured.
|
Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
|
Change in plasma time to reach maximal concentration (Tmax) of phenolic metabolites after acute ingestion of the supplement/placebo
Tidsramme: Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
Plasma samples will be collected in EDTA tubes in baseline before supplement/placebo intake (0h) and up to 24h according to the time frame.
Phenolic compounds metabolites in plasma will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids, and flavonoids derivatives.
For each identified and quantified metabolite the time to reach maximum concentration in hour is measured.
|
Baseline (pre-ingestion) and 0.5 hour, 1 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 24 hour post-ingestion
|
|
Change in urine area under the curve (AUC) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Tidsramme: Baseline (pre-ingestion) to 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the area under the curve (0-24 hour) in nmol/L-h is measured.
|
Baseline (pre-ingestion) to 48 hour post-ingestion
|
|
Change in urine maximal concentration (Cmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Tidsramme: Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are penylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the maximal concentration in nmol/L is measured.
|
Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
|
Change in urine time to reach maximal concentration (Tmax) phenolic metabolites excretion after acute ingestion of the supplement/placebo
Tidsramme: Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Urine samples will be collected in baseline (0h pre-ingestion) and up to 48h according to the time frame.
Phenolic compounds metabolites in urine will be identified and quantified by HPLC-MS.
Targeted metabolites are prenylated phenolic acids, phenolic acids and flavonoids derivatives.
For each identified and quantified metabolite the time to reach maximum concentration in hour is measured.
|
Baseline (pre-ingestion) and 0 hour - 3 hour, 3 hour - 6 hour, 6 hour - 10 hour, 10 hour - 14 hour, 14 hour - 24 hour, 24 hour - 36 hour and 36 hour - 48 hour post-ingestion
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. juni 2026
Primær færdiggørelse (Anslået)
1. juli 2026
Studieafslutning (Anslået)
1. juli 2026
Datoer for studieregistrering
Først indsendt
26. juni 2026
Først indsendt, der opfyldte QC-kriterier
26. juni 2026
Først opslået (Faktiske)
2. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
2. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- GREENKBA
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .